ATYR (aTyr Pharma) LT-Debt-to-Total-Asset : 0.14 (As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is aTyr Pharma LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. aTyr Pharma's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.14.

aTyr Pharma's long-term debt to total assets ratio increased from Sep. 2023 (0.11) to Sep. 2024 (0.14). It may suggest that aTyr Pharma is progressively becoming more dependent on debt to grow their business.

aTyr Pharma LT-Debt-to-Total-Asset Historical Data

The historical data trend for aTyr Pharma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

aTyr Pharma LT-Debt-to-Total-Asset Chart

aTyr Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.06

0.04

0.11

aTyr Pharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.11	0.11	0.12	0.12	0.14

aTyr Pharma LT-Debt-to-Total-Asset Calculation

aTyr Pharma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	13.767	/	120.653
	=	0.11

aTyr Pharma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	12.359	/	91.616
	=

aTyr Pharma (NAS:ATYR) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

aTyr Pharma LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of aTyr Pharma's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

aTyr Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » aTyr Pharma Inc (NAS:ATYR) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

471A:Germany

Address

10240 Sorrento Valley Road, Suite 300, San Diego, CA, USA, 92121

Website

https://www.atyrpharma.com

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

Executives

Paul Schimmel	director	88 SIDNEY ST, CAMBRIDGE MA 02139
Jill Marie Broadfoot	officer: Chief Financial Officer	3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Sanjay Shukla	officer: Chief Medical Officer	C/O ATYR PHARMA, INC., 10240 SORRENTO VALLEY ROAD, SUITE 300, SAN DIEGO CA 92121
Timothy P Coughlin	director	339 NORTH GRANADOS AVE, SOLANA BEACH CA 92075
Sara Zaknoen	director	C/O IGNYTA, INC., 11095 FLINTKOTE AVENUE, SUITE D, SAN DIEGO CA 92121
John K Clarke	director	C/O CARDINAL HEALTH PARTNERS, 221 NASSAU STREET, PRINCETON NJ 08542
Nancy Krueger	officer: See Remarks	C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Svetlana Lucas	director	3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Jane A Gross	director	2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
John Mendlein	director, officer: CEO and Executive Chairman
Ecor1 Capital Fund Qualified, L.p.	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ashraf Amanullah	officer: Vice President, Manufacturing	C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
John T Blake	officer: Vice President, Finance	C/O SECOND SIGHT MEDICAL PRODUCTS, INC., 12744 SAN FERNANDO ROAD, SUITE 400, SYLMAR CA 91342
Jeffrey S. Hatfield	director	11080 ROSELLE STREET, SAN DIEGO CA 92121
David John King	officer: See Remarks	3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121